These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9631890)

  • 41. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
    Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
    Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. When urokinase was gone: commentary on another year of thrombolysis without urokinase.
    Gates J; Hartnell GG
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):1-5. PubMed ID: 14709680
    [No Abstract]   [Full Text] [Related]  

  • 44. Coagulation and fibrinolysis study after local thrombolysis of a cerebral artery with urokinase.
    Oyama H; Iwakoshi T; Niwa M; Kida Y; Tanaka T; Kitamura R; Maezawa S; Kobayashi T
    Neurol Med Chir (Tokyo); 1996 May; 36(5):300-4. PubMed ID: 8710052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment.
    Lim GM; Bookstein JJ
    J Vasc Interv Radiol; 1998; 9(4):618-25. PubMed ID: 9684833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Danger of urokinase as an anticoagulant with left ventricular assist devices.
    Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
    ASAIO J; 1995; 41(3):M787-90. PubMed ID: 8573915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.
    Le A; Zhang L; Liu W; Li X; Ren J; Ning A
    Medicine (Baltimore); 2017 Feb; 96(7):e6116. PubMed ID: 28207534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thrombolysis by rotational thrombectomy followed by tissue plasminogen activator: evaluation by angioscopy.
    Johnson CC; Dewhurst TA; Vracko R; Auth DC; Ritchie JL
    Cathet Cardiovasc Diagn; 1991 Nov; 24(3):214-20. PubMed ID: 1764746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential thrombolysis under selective infusion of autologous plasmin (AP) solution.
    Mizutani M; Kobayashi T; Makita M; Miyamoto A; Kanamori K; Hasegawa H; Yasuda H
    Jpn Heart J; 1989 Sep; 30(5):723-32. PubMed ID: 2533283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction.
    Goto S; Handa S; Kawai Y; Watanabe K; Abe S; Takahashi E; Hori S; Ikeda Y
    Cardiology; 1992; 80(3-4):252-6. PubMed ID: 1387346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inducible carboxypeptidase activity. A role in clot lysis in vivo.
    Redlitz A; Nicolini FA; Malycky JL; Topol EJ; Plow EF
    Circulation; 1996 Apr; 93(7):1328-30. PubMed ID: 8641019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase.
    Takada A; Takada Y; Uemura K; Nakajima S; Ryu H; Ninchoji T
    Thromb Res; 1979; 15(5-6):889-94. PubMed ID: 115108
    [No Abstract]   [Full Text] [Related]  

  • 53. Studies on the effect of PEG-modified urokinase on coagulation-fibrinolysis using beagles.
    Sakuragawa N; Shimizu K; Kondo K; Kondo S; Niwa M
    Thromb Res; 1986 Mar; 41(5):627-35. PubMed ID: 3961739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Macromolecular ensembles of internal and external fibrinolysis: the resources for enhancement of thrombolysis efficacy.
    Maksimenko AV; Tischenko EG
    Curr Med Chem; 2006; 13(14):1617-25. PubMed ID: 16787208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing the bolus/infusion ratio for intravenous administration of urokinase in dogs.
    Klabunde RE; Hemenway CC; Mohrman SJ; Henkin J; Badylak SF
    Thromb Res; 1988 Jun; 50(6):857-64. PubMed ID: 2457959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of suprachoroidal hemorrhage with tissue plasminogen activator.
    Kwon OW; Kang SJ; Lee JB; Lee SC; Yoon YD; Oh JH
    Ophthalmologica; 1998; 212(2):120-5. PubMed ID: 9486552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage.
    Hawkins WR
    Am J Ophthalmol; 1995 Oct; 120(4):550-2. PubMed ID: 7573328
    [No Abstract]   [Full Text] [Related]  

  • 58. The role of fibrinolysis in the therapy of peripheral vascular disease.
    Ambrus CM; Ambrus JL; Gastpar H; Sharma SD; Suh OW; Moore RH; Williams P
    Angiology; 1984 Jul; 35(7):436-42. PubMed ID: 6235758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.
    Shuster KA; Wrobleski SK; Hawley AE; Lucchesi BR; Sorenson DR; Bergin IL; Sigler RE; Guire KE; Nowland MH; Wakefield TW; Myers DD
    Comp Med; 2013 Jun; 63(3):244-51. PubMed ID: 23759527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical use of tissue plasminogen activator for systemic thrombolysis in dogs and cats.
    Diaz DM; Scansen BA; Lake Z; Shropshire S; Orton EC; Guillaumin J
    J Vet Cardiol; 2022 Jun; 41():154-164. PubMed ID: 35364502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.